Prestige Consumer Healthcare Inc. (NYSE:PBH) reported fiscal second-quarter 2026 results on Thursday that topped analyst estimates, as earnings outperformed expectations despite lingering supply challenges in its eye care division.
The healthcare products maker posted adjusted earnings per share of $1.07, exceeding the consensus estimate of $0.97. Revenue came in at $274.1 million, above expectations of $257.42 million, though down 3.4% year over year from $283.8 million. The decline was largely due to supply limitations for its Clear Eyes line.
“Our second quarter results surpassed our sales and earnings expectations helped primarily by Clear Eyes supply timing and the timing of certain retailer orders,” said Ron Lombardi, Chief Executive Officer of Prestige Consumer Healthcare.
Revenue from the company’s North American OTC Healthcare segment slipped to $230.8 million from $239.8 million a year earlier, while International OTC Healthcare sales edged down slightly to $43.4 million from $44.0 million.
Despite these headwinds, Prestige maintained its full-year 2026 revenue guidance of $1.10–$1.11 billion but raised its adjusted EPS forecast to $4.54–$4.58, marking the upper end of its prior range and above the $4.51 analyst consensus.
During the quarter, Prestige repurchased around 1.1 million shares for approximately $75 million, underscoring its commitment to shareholder returns through strong free cash flow generation.
“We remain committed to rebuilding long-term supply chain capacity in Clear Eyes and expect to close the Pillar5 transaction as planned,” Lombardi added, emphasizing the company’s strategy to strengthen production and restore growth in its eye care portfolio.